Yuta Takagaki, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Nephropathies | 7 | 2022 | 973 | 1.400 |
Why?
|
| Dipeptidyl Peptidase 4 | 4 | 2020 | 91 | 1.120 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2022 | 1119 | 0.800 |
Why?
|
| Fibrosis | 5 | 2020 | 2049 | 0.730 |
Why?
|
| Epithelial-Mesenchymal Transition | 5 | 2020 | 736 | 0.570 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2019 | 311 | 0.530 |
Why?
|
| Kidney | 6 | 2022 | 7048 | 0.400 |
Why?
|
| Autophagy | 1 | 2020 | 1326 | 0.390 |
Why?
|
| Interleukin-6 | 1 | 2020 | 3208 | 0.340 |
Why?
|
| Endothelial Cells | 2 | 2020 | 3548 | 0.340 |
Why?
|
| Kidney Diseases | 2 | 2018 | 2091 | 0.330 |
Why?
|
| Kidney Tubules | 2 | 2019 | 449 | 0.270 |
Why?
|
| Glycolysis | 2 | 2020 | 835 | 0.260 |
Why?
|
| Glucosides | 2 | 2020 | 512 | 0.230 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 3085 | 0.230 |
Why?
|
| Veterinary Drugs | 1 | 2002 | 2 | 0.210 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 2002 | 44 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 5840 | 0.200 |
Why?
|
| Serum Albumin, Bovine | 2 | 2022 | 321 | 0.200 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2022 | 108 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 2 | 2020 | 1961 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 2057 | 0.180 |
Why?
|
| Superior Mesenteric Artery Syndrome | 1 | 2020 | 7 | 0.180 |
Why?
|
| Thiazolidines | 1 | 2019 | 69 | 0.160 |
Why?
|
| Pyridazines | 1 | 2020 | 202 | 0.160 |
Why?
|
| Hypertrophy | 1 | 2021 | 561 | 0.160 |
Why?
|
| Smad3 Protein | 1 | 2019 | 166 | 0.160 |
Why?
|
| Culture Media | 1 | 2020 | 897 | 0.150 |
Why?
|
| Caveolin 1 | 1 | 2019 | 256 | 0.140 |
Why?
|
| Chemokine CXCL12 | 1 | 2018 | 454 | 0.140 |
Why?
|
| Thinness | 1 | 2020 | 490 | 0.130 |
Why?
|
| Microcirculation | 1 | 2020 | 1273 | 0.120 |
Why?
|
| Pyrroles | 1 | 2020 | 1125 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 727 | 0.110 |
Why?
|
| Thiophenes | 1 | 2018 | 569 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 916 | 0.110 |
Why?
|
| Metformin | 1 | 2020 | 906 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 2176 | 0.100 |
Why?
|
| Mice | 9 | 2022 | 81525 | 0.100 |
Why?
|
| Streptozocin | 2 | 2022 | 194 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2022 | 23445 | 0.090 |
Why?
|
| Cell Movement | 2 | 2020 | 5203 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 3429 | 0.090 |
Why?
|
| Animals | 11 | 2022 | 168459 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 3492 | 0.080 |
Why?
|
| Homeostasis | 1 | 2020 | 3323 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2019 | 2009 | 0.080 |
Why?
|
| Weight Loss | 1 | 2020 | 2684 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 4431 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 9539 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 12148 | 0.070 |
Why?
|
| Mitochondria | 1 | 2018 | 3624 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 9420 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 22169 | 0.060 |
Why?
|
| Hexestrol | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lasalocid | 1 | 2002 | 5 | 0.050 |
Why?
|
| Chlortetracycline | 1 | 2002 | 5 | 0.050 |
Why?
|
| Drug Residues | 1 | 2002 | 7 | 0.050 |
Why?
|
| Monensin | 1 | 2002 | 30 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 6132 | 0.050 |
Why?
|
| Pyrans | 1 | 2002 | 49 | 0.050 |
Why?
|
| Pyrimethamine | 1 | 2002 | 94 | 0.050 |
Why?
|
| Transforming Growth Factors | 1 | 2022 | 75 | 0.050 |
Why?
|
| Leukemia, Experimental | 1 | 2002 | 225 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 21012 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 11903 | 0.050 |
Why?
|
| Collagen Type III | 1 | 2022 | 91 | 0.050 |
Why?
|
| Phenotype | 1 | 2020 | 16591 | 0.050 |
Why?
|
| Receptors, IgE | 1 | 2002 | 375 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 18252 | 0.050 |
Why?
|
| Doxycycline | 1 | 2002 | 344 | 0.040 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2002 | 347 | 0.040 |
Why?
|
| Pyruvate Kinase | 1 | 2020 | 189 | 0.040 |
Why?
|
| Proteinuria | 1 | 2022 | 607 | 0.040 |
Why?
|
| Humans | 9 | 2022 | 761504 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 496 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 383 | 0.040 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2018 | 89 | 0.040 |
Why?
|
| Adenosine | 1 | 2022 | 808 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 619 | 0.030 |
Why?
|
| Sodium | 1 | 2022 | 1588 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13380 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2018 | 3615 | 0.030 |
Why?
|
| Testosterone | 1 | 2002 | 2472 | 0.020 |
Why?
|
| Male | 5 | 2021 | 360804 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3602 | 0.020 |
Why?
|
| Energy Intake | 1 | 2018 | 2134 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4346 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 6216 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 4915 | 0.020 |
Why?
|
| Prognosis | 2 | 2021 | 29625 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 3712 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2021 | 6391 | 0.020 |
Why?
|
| Rats | 1 | 2002 | 23742 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 7407 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13506 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10445 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 9486 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8547 | 0.010 |
Why?
|
| Female | 4 | 2021 | 392644 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39106 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 80636 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 169289 | 0.000 |
Why?
|
| Middle Aged | 1 | 2020 | 220895 | 0.000 |
Why?
|